Life sciences stands at a critical juncture. As traditional animal testing faces both ethical and scientific limitations, organoid technology and AI-based modeling offer new hope. In this newsletter, we explore the challenges confronting modern biotechnology and the innovative solutions emerging on the horizon.
Growing ethical concerns and scientific limitations demand a shift away from animal testing in biotech. In November 2024, Le Monde – one of the major newsletters in France, highlighted growing ethical debates and scientific doubts about animal experimentation. Despite its long-standing role in drug and therapy development, critics argue that animal models often fail to accurately predict human responses. The article cites studies showing that over 90% of drugs successful in animal trials fail in human clinical stages, exposing inefficiencies. The organisation Pro Anima explains that advances in organoid technology and AI-driven modelling offer more predictive, humane alternatives. In addition, to foster innovation and uphold ethical standards, the bio-health sector must accelerate the adoption of non-animal testing methods. The article’s publication in Le Monde sparks public debate, pressures regulatory bodies, and drives biotech innovation, urging a shift towards humane, ethical, and more accurate testing methods.
